31 reports

  • REST OF THE WORLD RNAI TECHNOLOGY MARKET, 2014-2022 (IN USD MILLION)
  • GLOBAL RNAI TECHNOLOGY MARKET, 2014-2022 (IN USD MILLION)

RNAi Technology Market The market for RNAi technology is estimated to be USD 12.56 billion in 2016 and is expected to reach USD 31.52 billion by 2021, growing at a CAGR of 20.19% RNA interference (RNAi) is a natural process of treating forms of cancer and other diseases by post-transcriptional silencing of genes by small fragments...

  • RNA Interference
  • World
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc.
  • Sirna Therapeutics, Inc.

The 2019-2024 World Outlook for Antisense and RNA Interference (RNAi) Therapeutics ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Biological Therapy
  • RNA Interference
  • RNAi
  • World
  • Demand

RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE ## U. S. antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE ## U. S. antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)

  • Biological Therapy
  • RNA Interference
  • Therapy
  • United States
  • Market Size

REASONS FOR DOING THIS STUDY The RNAi market is burgeoning and is one of the most watched markets in the pharmaceuticals industry.

  • Biological Therapy
  • RNA Interference
  • World
  • Market Shares
  • Market Size

RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025: Prospects for siRNAs, shRNAs and ddRNAi Approaches Table of Contents ##.

  • Biological Therapy
  • RNA Interference
  • RNAi
  • World
  • Market Size

## RNAI AS THERAPY ## THE PROMISE OF RNAI ## TABLE ## VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION ## RNAI TECHNOLOGY ## RNAI MECHANISM: HOW DOES IT WORK?

  • Biological Therapy
  • RNA Interference
  • RNAi
  • World
  • Forecast

Global RNA Interference (RNAi) Therapy Market Outlook 2018 ##.

  • Biological Therapy
  • RNA Interference
  • RNAi
  • RNAi Technology
  • World

Agrow: RNAi

2709 2980 2303

Agrow: RNAi Contents ## Executive Summary ## Chapter ##: Introduction ## Chapter ##: RNAi for controlling insects and other pests ## Chapter ##: RNAi in other crop sectors ## Chapter ##: Formulation and delivery of RNAi technology ## Chapter ##: Crop p

  • Biological Therapy
  • RNA Interference
  • RNAi Technology
  • United States
  • Litigation And Patent
  • May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
  • Alnylam Pharmaceuticals Inc - Corporate Strategy

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities...

  • Pharmaceutical
  • RNA Interference
  • RNAi
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • Dicerna Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe & Hamilton RNAi Patents
  • Feb 02, 2017: Dicerna Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies.The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. It offers RNAi technology platform GalXCTM, which is a advances the development...

  • Healthcare
  • Pharmaceutical
  • RNA Interference
  • Therapy
  • Dicerna Pharmaceuticals, Inc.
  • Oct 18, 2017: U.S. patent granted for Benitec hepatitis B program
  • Benitec Biopharma Ltd, Major Products and Services

Benitec Biopharma Ltd (BLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats....

  • Biopharmaceutical
  • Hepatitis
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited
  • RNAI OLIGONUCLEOTIDE FOR UNDISCLOSED INDICATION
  • RNAI OLIGONUCLEOTIDES FOR GENETIC DISEASES

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Pharmaceutical
  • Research And Development
  • RNA Interference
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • Benitec Biopharma Ltd, Subsidiaries
  • 04/21/2016: Benitec to present data on muscular dystrophy program at the ASGCT 2016 Annual Meeting

DEAL RATIONALE Cal-## is under development for the treatment of HIV-## Infection.

  • Biopharmaceutical
  • Healthcare
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited
  • ANTISENSE RNAI OLIGONUCLEOTIDE TO INHIBIT BETA CATENIN FOR ONCOLOGY - DRUG PROFILE
  • Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016

Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016’, provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information...

  • Biotech
  • RNA Interference
  • World
  • Product Initiative
  • Marina Biotech, Inc.
  • ALNYLAM PHARMA AND GENZYME ENTER INTO AGREEMENT FOR RNAI THERAPEUTICS AS GENETIC MEDICINES
  • MEDICINES COMPANY ENTERS INTO LICENSING AGREEMENT WITH ALNYLAM PHARMA TO DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS TARGETING PCSK9

Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi).The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease;...

  • Pharmaceutical
  • RNA Interference
  • RNAi
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • Jun 12, 2017: Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
  • Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity

Results from the Phase ## study were published in The New England Journal of Medicine in a paper titled, " Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.

  • Pharmaceutical
  • RNA Interference
  • Therapy
  • United States
  • Alnylam Pharmaceuticals, Inc.
  • PARTNERSHIPS
  • Mar 28, 2017: Silence Therapeutics: Preliminary results for the year to 31 December 2016

It is based on RNAi therapeutics.

  • Pharmaceutical
  • RNA Interference
  • Therapy
  • United Kingdom
  • Silence Therapeutics
  • FEB 07, 2017: RXI PHARMACEUTICALS APPOINTS LEADING ONCOLOGY EXPERT, DR. ROLF KIESSLING, TO SCIENTIFIC ADVISORY BOARD
  • LICENSING AGREEMENTS

Summary RXi Pharmaceuticals Corp (RXi) is a biotechnology company that discovers, develops and commercializes immuno-oncology therapeutics to treat cancer.The company’s technology sd-rxRNA includes RXI-109 and IncRNA. Its lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue...

  • RNA Interference
  • Therapy
  • United States
  • Company Operations
  • RXi Pharmaceuticals Corporation
  • Proliferative Vitreoretinopathy (PVR) - Drug Profiles
  • RXI PHARMACEUTICALS CORP

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H1 2017, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. Proliferative...

  • RNA Interference
  • Therapy
  • United States
  • Product Initiative
  • RXi Pharmaceuticals Corporation
  • ARROWHEAD RESEARCH ACQUIRES RNAI R&D PORTFOLIO FROM NOVARTIS FOR USD35 MILLION
  • APR 18, 2016: ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON RENAL CELL CARCINOMA PROGRAM AT AACR 2016

Summary Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp is a pharmaceutical company that develops medicines that treat intractable diseases.The company develops pipeline drugs that are being developed to treat chronic hepatitis B virus infection for the treatment of liver disease, thrombosis...

  • Pharmaceutical
  • RNA Interference
  • Therapy
  • United States
  • Corporate Finance
  • PARTNER 1: GENEDESIGN INC

Alnylam Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s Alnylam Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A),...

  • RNA Interference
  • RNAi Technology
  • United States
  • Corporate Finance
  • Alnylam Pharmaceuticals, Inc.
  • Business description
  • PARTNERSHIP

Arbutus Biopharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s Arbutus Biopharma Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A),...

  • Biopharmaceutical
  • Pharmaceutical
  • RNA Interference
  • RNAi Technology
  • Arbutus Biopharma Corporation

Alnylam Pharmaceuticals Cancer Drugs Clinical Pipeline Insight ##.

  • Biological Therapy
  • Pharmaceutical
  • RNA Interference
  • Therapy
  • United States
  • Product Description
  • R&D Progress

Benitec Biopharma Limited - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Benitec Biopharma Limited - Product Pipeline Review - 2015’, provides an overview of the Benitec Biopharma Limited’s pharmaceutical research and development focus. This report provides comprehensive information on the current...

  • Biopharmaceutical
  • Hepatitis
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited

Madison, Box ## Seattle Washington United States www. halo-bio. com ## ## ## ## Private COMPANY INFORMATION: PARTNERS PARTNER ##: HALO-BIO RNAI THERAPEUTICS, INC.

  • RNA Interference
  • RNAi Technology
  • United States
  • Corporate Finance
  • Tekmira Pharmaceuticals Corporation
  • RNA INTERFERENCE FOR HEPATOCELLULAR CARCINOMA PRODUCT DESCRIPTION
  • RNAI OLIGONUCLEOTIDES FOR HEPATITIS C PRODUCT DESCRIPTION

Arrowhead Research Corporation - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Arrowhead Research Corporation - Product Pipeline Review - 2015’, provides an overview of the Arrowhead Research Corporation’s pharmaceutical research and development focus. This report provides comprehensive information...

  • RNA Interference
  • RNAi Technology
  • United States
  • Company Operations
  • Arrowhead Research Corporation
  • RXI PHARMACEUTICALS CORPORATION - DORMANT DEVELOPMENTAL PROJECTS,2016
  • RXI PHARMACEUTICALS CORPORATION - PRECLINICAL, 2016

RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016’, provides an overview of the RXi Pharmaceuticals Corporation’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Pharmaceutical
  • Research And Development
  • RNA Interference
  • Therapy
  • RXi Pharmaceuticals Corporation
  • DEAL REPORT: CENIX AND CELLCENTRIC SIGNS RESEARCH AGREEMENT FOR RNAI-BASED TARGET VALIDATION
  • DEAL REPORT: CENIX BIOSCIENCE SIGNS RESEARCH AGREEMENT WITH BOEHRINGER INGELHEIM FOR RNAI-BASED TARGET DISCOVERY

Project Synopsis: Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Project Description: Datamonitors' Cenix BioScience...

  • Pharmaceutical
  • RNA Interference
  • Therapy
  • Company
  • Cenix BioScience GmbH
  • MERGERS AND ACQUISITIONS - DEAL REPORTS

Summary Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. This report includes Silence Therapeutics plc's contact information and...

  • RNA Interference
  • Therapy
  • United States
  • Corporate Finance
  • Silence Therapeutics
  • HYPERTROPHIC SCARS - PIPELINE BY RXI PHARMACEUTICALS CORPORATION, H2 2015
  • NUMBER OF PRODUCTS BY STAGE AND MOLECULE TYPE, H2 2015

Hypertrophic Scars - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Hypertrophic Scars - Pipeline Review, H2 2015’, provides an overview of the Hypertrophic Scars’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hypertrophic Scars, complete with...

  • Research And Development
  • RNA Interference
  • United States
  • Company Operations
  • RXi Pharmaceuticals Corporation